![5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-, rel-](https://img.chemicalbook.com/CAS/20210305/GIF/1639357-93-9.gif)
LN-054927
5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-[(3aR,6aS)-hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl]-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-, rel- , 98% , 1639357-93-9
Update time: 2023-04-23
PRODUCT Properties
| Boiling point: | 747.0±60.0 °C(Predicted) |
| Density | 1.49±0.1 g/cm3(Predicted) |
| form | Solid |
| pka | 8.53±0.20(Predicted) |
| color | White to off-white |
Description and Uses
ZYN57939 is RNA polymerase I inhibitor for treating RNA polymerase I-mediated diseases. ZYN57939 was first reported in CN 104177379 A 20141203 (2014). ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT-29 cancer cell lines. This product has no formal name at the moment.
MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer[1].
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319 |
| Precautionary statements | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |